{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T03:14:30Z","timestamp":1783394070876,"version":"3.54.6"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Beijing Science and Technology Innovation Medical Development Foundation","award":["KC2023-JX-0288-PM94"],"award-info":[{"award-number":["KC2023-JX-0288-PM94"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"DOI":"10.1186\/s13256-026-06105-9","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T15:04:11Z","timestamp":1778684651000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel strategy of pemetrexed combined with localized therapy: breakthrough impact of long-term maintenance regimen on patient survival\u2014a case report"],"prefix":"10.1186","volume":"20","author":[{"given":"Dan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobiao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlei","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqing","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"issue":"1","key":"6105_CR1","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7\u201333.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"6105_CR2","doi-asserted-by":"publisher","first-page":"103","DOI":"10.4143\/crt.2022.264","volume":"55","author":"DS Jeon","year":"2023","unstructured":"Jeon DS, Kim HC, Kim SH, Kim TJ, Kim HK, Moon MH, Beck KS, Suh YG, Song C, Ahn JS, et al. Five-year overall survival and prognostic factors in patients with lung cancer: results from the Korean Association of Lung Cancer Registry (KALC-R) 2015. Cancer Res Treat. 2023;55(1):103\u201311.","journal-title":"Cancer Res Treat"},{"issue":"5","key":"6105_CR3","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","volume":"135","author":"C Xia","year":"2022","unstructured":"Xia C, Dong X, Li H, Cao M, Sun D, He S, Yang F, Yan X, Zhang S, Li N, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl). 2022;135(5):584\u201390.","journal-title":"Chin Med J (Engl)"},{"issue":"7","key":"6105_CR4","doi-asserted-by":"publisher","first-page":"e342","DOI":"10.1016\/S1470-2045(20)30073-5","volume":"21","author":"W Wei","year":"2020","unstructured":"Wei W, Zeng H, Zheng R, Zhang S, An L, Chen R, Wang S, Sun K, Matsuda T, Bray F, et al. Cancer registration in China and its role in cancer prevention and control. Lancet Oncol. 2020;21(7):e342\u20139.","journal-title":"Lancet Oncol"},{"issue":"12","key":"6105_CR5","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1002\/cncr.30000","volume":"122","author":"PH Goncalves","year":"2016","unstructured":"Goncalves PH, Peterson SL, Vigneau FD, Shore RD, Quarshie WO, Islam K, Schwartz AG, Wozniak AJ, Gadgeel SM. Risk of brain metastases in patients with nonmetastatic lung cancer: analysis of the Metropolitan Detroit Surveillance, Epidemiology, and End Results (SEER) data. Cancer. 2016;122(12):1921\u20137.","journal-title":"Cancer"},{"key":"6105_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107322","volume":"184","author":"X Yan","year":"2023","unstructured":"Yan X, Qu F, Zhou Y. Progress of immune checkpoint inhibitors therapy for non-small cell lung cancer with brain metastases. Lung Cancer. 2023;184: 107322.","journal-title":"Lung Cancer"},{"key":"6105_CR7","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.16823","volume":"12","author":"Y Du","year":"2024","unstructured":"Du Y, Li H, Wang Y, He Y, Li G. DLX1 acts as a novel prognostic biomarker involved in immune cell infiltration and tumor progression in lung adenocarcinoma. PeerJ. 2024;12: e16823.","journal-title":"PeerJ"},{"issue":"8","key":"6105_CR8","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1158\/1078-0432.CCR-20-4023","volume":"27","author":"KC Arbour","year":"2021","unstructured":"Arbour KC, Rizvi H, Plodkowski AJ, Hellmann MD, Knezevic A, Heller G, Yu HA, Ladanyi M, Kris MG, Arcila ME, et al. Treatment outcomes and clinical characteristics of patients with KRAS-G12C-mutant non-small cell lung cancer. Clin Cancer Res. 2021;27(8):2209\u201315.","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"6105_CR9","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41379-021-00932-5","volume":"35","author":"LM Sholl","year":"2022","unstructured":"Sholl LM. Biomarkers of response to checkpoint inhibitors beyond PD-L1 in lung cancer. Mod Pathol. 2022;35(Suppl 1):66\u201374.","journal-title":"Mod Pathol"},{"issue":"6","key":"6105_CR10","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1200\/JCO.21.01845","volume":"40","author":"A Passaro","year":"2022","unstructured":"Passaro A, Brahmer J, Antonia S, Mok T, Peters S. Managing resistance to immune checkpoint inhibitors in lung cancer: treatment and novel strategies. J Clin Oncol. 2022;40(6):598\u2013610.","journal-title":"J Clin Oncol"},{"key":"6105_CR11","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231175438","volume":"15","author":"RD Merkin","year":"2023","unstructured":"Merkin RD, Chiang VL, Goldberg SB. Management of patients with brain metastases from NSCLC without a genetic driver alteration: upfront radiotherapy or immunotherapy? Ther Adv Med Oncol. 2023;15: 17588359231175438.","journal-title":"Ther Adv Med Oncol"},{"issue":"12","key":"6105_CR12","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s40264-021-01135-2","volume":"44","author":"N de Rouw","year":"2021","unstructured":"de Rouw N, Piet B, Derijks HJ, van den Heuvel MM, Ter Heine R. Mechanisms, management and prevention of Pemetrexed-related toxicity. Drug Saf. 2021;44(12):1271\u201381.","journal-title":"Drug Saf"},{"issue":"2","key":"6105_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/JTO.0000000000000076","volume":"9","author":"M Reck","year":"2014","unstructured":"Reck M, Paz-Ares LG, de Marinis F, Molinier O, Sahoo TP, Laack E, John W, Zimmermann AH, Visseren-Grul C, Gridelli C. PARAMOUNT: descriptive subgroup analyses of final overall survival for the phase III study of maintenance pemetrexed versus placebo following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2014;9(2):205\u201313.","journal-title":"J Thorac Oncol"},{"issue":"6","key":"6105_CR14","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1093\/annonc\/mdt123","volume":"24","author":"C Obasaju","year":"2013","unstructured":"Obasaju C, Bowman L, Wang P, Shen W, Winfree KB, Smyth EN, Boye ME, John W, Brodowicz T, Belani CP. Identifying the target NSCLC patient for maintenance therapy: an analysis from a placebo-controlled, phase III trial of maintenance pemetrexed (H3E-MC-JMEN). Ann Oncol. 2013;24(6):1534\u201342.","journal-title":"Ann Oncol"},{"issue":"3","key":"6105_CR15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S1470-2045(12)70063-3","volume":"13","author":"L Paz-Ares","year":"2012","unstructured":"Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012;13(3):247\u201355.","journal-title":"Lancet Oncol"},{"issue":"3","key":"6105_CR16","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/S1470-2045(11)70339-4","volume":"13","author":"CP Belani","year":"2012","unstructured":"Belani CP, Brodowicz T, Ciuleanu TE, Krzakowski M, Yang SH, Franke F, Cucevic B, Madhavan J, Santoro A, Ramlau R, et al. Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study. Lancet Oncol. 2012;13(3):292\u20139.","journal-title":"Lancet Oncol"},{"issue":"3","key":"6105_CR17","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.lungcan.2015.11.011","volume":"90","author":"D Moro-Sibilot","year":"2015","unstructured":"Moro-Sibilot D, Smit E, de Castro Carpe\u00f1o J, Lesniewski-Kmak K, Aerts JG, Villatoro R, Kraaij K, Nacerddine K, Dyachkova Y, Smith KT, et al. Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: analysis from the European FRAME study. Lung Cancer. 2015;90(3):427\u201332.","journal-title":"Lung Cancer"},{"issue":"5.5","key":"6105_CR18","first-page":"574","volume":"17","author":"MA Gubens","year":"2019","unstructured":"Gubens MA, Davies M. NCCN guidelines updates: new immunotherapy strategies for improving outcomes in non-small cell lung cancer. J Natl Compr Canc Netw. 2019;17(5.5):574\u20138.","journal-title":"J Natl Compr Canc Netw"},{"issue":"21","key":"6105_CR19","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","volume":"26","author":"GV Scagliotti","year":"2008","unstructured":"Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543\u201351.","journal-title":"J Clin Oncol"},{"issue":"1","key":"6105_CR20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/JTO.0b013e3181f7c6d4","volume":"6","author":"G Scagliotti","year":"2011","unstructured":"Scagliotti G, Brodowicz T, Shepherd FA, Zielinski C, Vansteenkiste J, Manegold C, Simms L, Fossella F, Sugarman K, Belani CP. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol. 2011;6(1):64\u201370.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"6105_CR21","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1097\/JTO.0b013e31823d4f9d","volume":"7","author":"CP Belani","year":"2012","unstructured":"Belani CP, Wu YL, Chen YM, Kim JH, Yang SH, Zhang L, Peterson P, Orlando M. Efficacy and safety of pemetrexed maintenance therapy versus best supportive care in patients from East Asia with advanced, nonsquamous non-small cell lung cancer: an exploratory subgroup analysis of a global, randomized, phase 3 clinical trial. J Thorac Oncol. 2012;7(3):567\u201373.","journal-title":"J Thorac Oncol"},{"issue":"6","key":"6105_CR22","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s00280-013-2142-9","volume":"71","author":"YH Kim","year":"2013","unstructured":"Kim YH, Hirabayashi M, Kosaka S, Nikaidoh J, Yamamoto Y, Shimada M, Toyazaki T, Nagai H, Sakamori Y, Mishima M. Phase II study of pemetrexed as first-line treatment in elderly (\u226575) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901. Cancer Chemother Pharmacol. 2013;71(6):1445\u201351.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"6105_CR23","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1007\/s11684-021-0867-0","volume":"16","author":"X Wang","year":"2022","unstructured":"Wang X, Wang M, Feng L, Song J, Dong X, Xiao T, Cheng S. Four-protein model for predicting prognostic risk of lung cancer. Front Med. 2022;16(4):618\u201326.","journal-title":"Front Med"},{"key":"6105_CR24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.lungcan.2022.01.010","volume":"165","author":"MG Faber","year":"2022","unstructured":"Faber MG, Wang C, Kommi Reddy S, Meagher A, Early A, Chen H, Dy GK. Survival outcomes of alternate dosing schedule of pemetrexed as maintenance therapy in NSCLC: single institution experience. Lung Cancer. 2022;165:49\u201353.","journal-title":"Lung Cancer"},{"issue":"8","key":"6105_CR25","first-page":"3275","volume":"13","author":"C Gan","year":"2023","unstructured":"Gan C, Li W, Xu J, Pang L, Tang L, Yu S, Li A, Ge H, Huang R, Cheng H. Advances in the study of the molecular biological mechanisms of radiation-induced brain injury. Am J Cancer Res. 2023;13(8):3275\u201399.","journal-title":"Am J Cancer Res"},{"issue":"9","key":"6105_CR26","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","volume":"22","author":"N Hanna","year":"2004","unstructured":"Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22(9):1589\u201397.","journal-title":"J Clin Oncol"},{"issue":"3","key":"6105_CR27","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.18632\/oncotarget.6184","volume":"7","author":"N Tang","year":"2016","unstructured":"Tang N, Guo J, Zhang Q, Wang Y, Wang Z. Greater efficacy of chemotherapy plus bevacizumab compared to chemo- and targeted therapy alone on non-small cell lung cancer patients with brain metastasis. Oncotarget. 2016;7(3):3635\u201344.","journal-title":"Oncotarget"},{"issue":"11","key":"6105_CR28","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1093\/annonc\/mdr003","volume":"22","author":"F Barlesi","year":"2011","unstructured":"Barlesi F, Gervais R, Lena H, Hureaux J, Berard H, Paillotin D, Bota S, Monnet I, Chajara A, Robinet G. Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07\u201301). Ann Oncol. 2011;22(11):2466\u201370.","journal-title":"Ann Oncol"},{"issue":"1","key":"6105_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-023-05268-2","volume":"24","author":"H Li","year":"2023","unstructured":"Li H, Yang L, Wang Y, Wang L, Chen G, Zhang L, Wang D. Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis. BMC Bioinformatics. 2023;24(1): 155.","journal-title":"BMC Bioinformatics"},{"key":"6105_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/cells10071669","author":"X Lou","year":"2021","unstructured":"Lou X, Ning J, Liu W, Li K, Qian B, Xu D, Wu Y, Zhang D, Cui W. YTHDF1 promotes cyclin B1 translation through m(6)A modulation and contributes to the poor prognosis of lung adenocarcinoma with KRAS\/TP53 co-mutation. Cells. 2021. https:\/\/doi.org\/10.3390\/cells10071669.","journal-title":"Cells"},{"key":"6105_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14215430","author":"P Cascetta","year":"2022","unstructured":"Cascetta P, Marinello A, Lazzari C, Gregorc V, Planchard D, Bianco R, Normanno N, Morabito A. KRAS in NSCLC: state of the art and future perspectives. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14215430.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"6105_CR32","first-page":"3233","volume":"17","author":"J Zhao","year":"2019","unstructured":"Zhao J, Han Y, Li J, Chai R, Bai C. Prognostic value of KRAS\/TP53\/PIK3CA in non-small cell lung cancer. Oncol Lett. 2019;17(3):3233\u201340.","journal-title":"Oncol Lett"},{"issue":"1","key":"6105_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47080-3","volume":"15","author":"YY Bi","year":"2024","unstructured":"Bi YY, Chen Q, Yang MY, Xing L, Jiang HL. Nanoparticles targeting mutant p53 overcome chemoresistance and tumor recurrence in non-small cell lung cancer. Nat Commun. 2024;15(1): 2759.","journal-title":"Nat Commun"},{"issue":"6","key":"6105_CR34","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.jtho.2022.02.011","volume":"17","author":"NI Vokes","year":"2022","unstructured":"Vokes NI, Chambers E, Nguyen T, Coolidge A, Lydon CA, Le X, Sholl L, Heymach JV, Nishino M, Van Allen EM, et al. Concurrent TP53 mutations facilitate resistance evolution in EGFR-mutant lung adenocarcinoma. J Thorac Oncol. 2022;17(6):779\u201392.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"6105_CR35","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41416-024-02746-z","volume":"131","author":"J Budczies","year":"2024","unstructured":"Budczies J, Romanovsky E, Kirchner M, Neumann O, Blasi M, Schnorbach J, Shah R, Bozorgmehr F, Savai R, Stiewe T, et al. KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma. Br J Cancer. 2024;131(3):524\u201333.","journal-title":"Br J Cancer"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-026-06105-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-06105-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-06105-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T02:28:44Z","timestamp":1783391324000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13256-026-06105-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6105"],"URL":"https:\/\/doi.org\/10.1186\/s13256-026-06105-9","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"assertion":[{"value":"16 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All procedures performed in this study were in accordance with the ethical standards of the institutional and\/or national research committee(s) and with the Helsinki Declaration (as revised in 2013). Written informed consent was obtained from the patient for the publication of this case report and accompanying images. A copy of the written consent is available for review by the editorial office of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declared no conflict of interest financial or otherwise.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"376"}}